Research programme: viral vaccines - Pharos Biologicals

Drug Profile

Research programme: viral vaccines - Pharos Biologicals

Latest Information Update: 11 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pharos Biologicals
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Viral infections

Highest Development Phases

  • Preclinical Zika virus infection
  • Research Dengue; Influenza virus infections

Most Recent Events

  • 11 May 2016 Research programme: viral vaccines - Pharos Biologicals is available for licensing as of 11 May 2016.
  • 02 May 2016 Pharos Biologicals plans a phase I trial for Zika virus infections
  • 02 May 2016 Pharos Biologicals in-licenses Lysosome-Associated Membrane Protein (LAMP) DNA vaccine technology from Johns Hopkins University School of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top